(Q44079528)

29 November 2017

title

Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update (English)

1 reference

29 November 2017

main subject

hepatocellular carcinoma

1 reference

3

1 reference

29 November 2017

4

Kenji Ikeda

1 reference

29 November 2017

Shuichi Kaneko

1

1 reference

29 November 2017

Junji Furuse

2

1 reference

29 November 2017

Masao Honda

5

1 reference

29 November 2017

Yasunari Nakamoto

6

1 reference

29 November 2017

Morikazu Onchi

7

1 reference

29 November 2017

Goshi Shiota

8

1 reference

29 November 2017

Osamu Yokosuka

9

1 reference

29 November 2017

Isao Sakaida

10

1 reference

29 November 2017

Tetsuo Takehara

11

1 reference

29 November 2017

Yoshiyuki Ueno

12

1 reference

29 November 2017

Kazumasa Hiroishi

13

1 reference

29 November 2017

Shuhei Nishiguchi

14

1 reference

29 November 2017

Hisataka Moriwaki

15

1 reference

29 November 2017

Kazuhide Yamamoto

16

1 reference

29 November 2017

Michio Sata

17

1 reference

29 November 2017

Shuntaro Obi

18

1 reference

29 November 2017

Shiro Miyayama

19

1 reference

29 November 2017

Yukinori Imai

20

1 reference

29 November 2017

publication date

1 June 2012

1 reference

29 November 2017

1 reference

29 November 2017

volume

42

1 reference

29 November 2017

issue

6

1 reference

29 November 2017

page(s)

523-542

1 reference

Sorafenib in advanced hepatocellular carcinoma

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a pha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Acquired resistance to miriplatin in rat hepatoma AH109A/MP10 is associated with increased Bcl-2 expression, leading to defects in inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

PIVKA-II is a predictive marker in the treatment response of sorafenib to hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.00981.X

10.1111/J.1872-034X.2012.00981.X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference